(redirected from Edarbi)


(a-zill-sar-tan) ,


(trade name)


Therapeutic: antihypertensives
Pharmacologic: angiotensin ii receptor antagonists
Pregnancy Category: D


Treatment of hypertension, alone or with other agents.


Blocks vasoconstrictor and aldosterone-producing effects of angiotensin II at receptor sites, including vascular smooth muscle and the adrenal glands.

Therapeutic effects

Lowering of BP.


Absorption: Azilsartan medoxomil, a prodrug, in hydrolyzed in the GI tract to azilsartan, the active component. 60% is absorbed from the GI tract.
Distribution: Approximately 16L.
Protein Binding: ≥99%.
Metabolism and Excretion: 50% metabolized by the liver, primarily by the CYP2C9 enzyme system. 55% eliminated in feces, 42% in urine (15% as unchanged drug).
Half-life: 11 hr.

Time/action profile (effect on BP)

POwithin 2 hr18 hr24 hr


Contraindicated in: Concurrent use with aliskiren in patients with diabetes or moderate-to-severe renal impairment (CCr <60 mL/min) Obstetric: Can cause injury or death of fetus – if pregnancy occurs, discontinue immediately. Lactation: Discontinue drug or use formula.
Use Cautiously in: genetic implication Black patients (may not be effective); HF (may result in potentially life-threatening renal failure); Renal impairment; may worsen renal function; Volume or salt depletion, including use of high-dose or potent diuretics may ↑ risk of serious hypotension; correct prior to use; Woman of childbearing potential; Geriatric: May have greater sensitivity, especially to adverse renal effects; Pediatric: Safety and effectiveness has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness
  • fatigue
  • weakness


  • hypotension (most frequent)

Fluid and Electrolyte

  • hyperkalemia


  • diarrhea (most frequent)
  • nausea


  • impaired renal function


  • muscle spasm


Drug-Drug interaction

Concurrent use of potassium-sparing diuretics, potassium-containing salt substitutes, or potassium supplements may ↑ risk of hyperkalemia.↑ risk of hyperkalemia, renal dysfunction, hypotension, and syncope with concurrent use of ACE inhibitors or aliskiren ; avoid concurrent use with aliskiren in patients with diabetes or CCr <60 mL/minNSAIDs and selective COX-2 inhibitors may blunt the antihypertensive effect and ↑ the risk of renal dysfunction.↑ antihypertensive effect with other antihypertensives or diuretics.


Oral (Adults) 80 mg once daily, initial dose may be ↓ to 40 mg once daily if high doses of diuretics are used concurrently.


Tablets: 40 mg, 80 mg
In combination with: chlorthalidone (Edarbyclor). See combination drugs.

Nursing implications

Nursing assessment

  • Assess BP (sitting, lying, standing) and pulse periodically during therapy.
  • Monitor frequency of prescription refills to determine adherence to therapy.
  • Lab Test Considerations: Monitor renal function. May cause small, reversible ↑ serum creatinine. May cause worsening renal function in patients with renal impairment. May rarely cause slight ↓ in RBC, hemoglobin and hematocrit.
    • May cause low and high markedly abnormal platelet and WBC.

Potential Nursing Diagnoses

Risk for injury (Adverse Reactions)
Noncompliance (Patient/Family Teaching)


  • Correct volume and salt depletion, if possible, before initiation of therapy, or start treatment at 40 mg.
  • Oral: Administer once daily without regard to food.

Patient/Family Teaching

  • Emphasize the importance of continuing to take as directed, even if feeling well. Take missed doses as soon as remembered if not almost before next dose; do not double doses. Medication controls but does not cure hypertension. Instruct patient to take medication at the same time each day. Warn patient not to discontinue therapy unless directed by health care professional.
  • Encourage patient to comply with additional interventions for hypertension (weight reduction, low-sodium diet, smoking cessation, moderation of alcohol consumption, regular exercise, and stress management). Medication controls but does not cure hypertension.
  • Instruct patient and family on proper technique for monitoring BP. Advise them to check BP at least weekly and to report significant changes.
  • Caution patient to avoid sudden position changes to decrease orthostatic hypotension. Use of alcohol, standing for long periods, exercising, and hot weather may ↑ orthostatic hypotension.
  • May cause dizziness. Caution patient to avoid driving and other activities requiring alertness until response to medication is known.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications, especially NSAIDs and cough, cold, or allergy medications.
  • Instruct patient to notify health care professional of medication regimen before treatment or surgery.
  • Advise women of childbearing age to use contraception and notify health care professional if pregnancy is planned or suspected, or if breastfeeding. Azilsartan should be discontinued as soon as possible when pregnancy is detected.
  • Emphasize the importance of follow-up exams to evaluate effectiveness of medication.

Evaluation/Desired Outcomes

  • ↓ in BP without excessive side effects.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Azilsartan (Edarbi; D) is an angiotensin II receptor blocker used for hypertension.
Azilsartan medoxomil, marketed as EDARBI in the US, lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone that naturally exists within the body.
Azilsartan medoxomil, marketed as Edarbi in the United States, reduces blood pressure by blocking the action of angiotensin II, a vasopressor hormone that is present naturally within the body.
23 September 2011 - Japanese drug maker Takeda Pharmaceutical Co Ltd (TYO:4502) said today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) provided a positive opinion on Edarbi, a new once-daily angiotensin II receptor antagonist (AIIRA), for the treatment of essential hypertension (high blood pressure).
gained FDA approval in February 2011 for Edarbi, a once-daily
M2 PHARMA-February 28, 2011-FDA greenlights Takeda's EDARBI for treatment of hypertension(C)2011 M2 COMMUNICATIONS
28 February 2011 - Japanese Takeda Pharmaceutical Company Limited (TYO: 4502) and its wholly-owned subsidiary, Takeda Pharmaceuticals North America Inc, said on Friday that the US Food and Drug Administration (FDA) has approved EDARBI (azilsartan medoxomil) for the treatment of hypertension in adults.
EDARBI is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone that constricts blood vessels.